Journal of Clinical and Experimental Hematopathology
Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280
Review Article
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
Shuntaro SaitoTsutomu Takeuchi
Author information

2019 Volume 59 Issue 4 Pages 145-155


Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients.

Information related to the author
© 2019 by The Japanese Society for Lymphoreticular Tissue Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Next article